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Abstract
Objective: To describe and discuss the design, building and usefulness of tissue microarray (TMA) blocks for the 
study of salivary gland tumors (SGTs). 
Study Design: Two hundred thirty-eight formalin-fixed, paraffin-embedded SGTs were arranged in blocks of 
TMA using a manual tissue arrayer. Three representative cores of 1.0, 2.0 or 3.0mm were taken from each original 
block and their characteristics were analyzed and described. 
Results: It was created 12 TMA blocks that presented highly representative neoplastic cylinders. However, those 
neoplasias rich in cystic spaces such as mucoepidermoid carcinoma and Warthin tumor presented more difficul-
ties to be sampled, as the neoplastic tissue available was scarce. Tissue damage and loss during TMA construction 
was estimated as 3.7%. 
Conclusion: Representative areas of SGTs, with relatively small loss of tissue, can be obtained with the construc-
tion of TMA blocks for molecular studies. However, tumors rich in cystic spaces present more difficulties to be 
adequately sampled. 
Key words: Tissue microarray, tma, salivary gland tumors, immunohistochemistry.
Paiva-Fonseca F, de-Almeida OP, Ayroza-Rangel ALC, Agustin-Vargas 
P. Tissue microarray construction for salivary gland tumors study. Med 
Oral Patol Oral Cir Bucal. 2013 Jan 1;18 (1):e1-6.   
 http://www.medicinaoral.com/medoralfree01/v18i1/medoralv18i1p1.pdf
Article Number: 18204          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.18204
http://dx.doi.org/doi:10.4317/medoral.18204
Introduction
Salivary gland tumors (SGT) are uncommon neoplasms 
that account for 6% of all head and neck neoplasias and 
0.3% of all cancers. The incidence of SGT per 100.000 
persons is reportedly as 0.9 in women and 1.5 in men, 
with varied biological behavior and clinical outcome 
(1,2). The development and progression of SGTs, like 
other neoplasias result from multiple genetic alterations 
and molecular studies may help to understand the me-
chanisms involved in their tumorigenesis.
The development of cDNA microarray and proteomic 
techniques, allowed the analysis of thousands of genes 
Med Oral Patol Oral Cir Bucal. 2013 Jan 1;18 (1):e1-6.                                                                                                                                                                               Tma in salivary gland tumors
   
e2
or proteins in one single experiment, facilitating the 
identification of molecules with potential clinical ap-
plications (3,4). In line with these new approaches, in 
1998 Kononen et al. (5) promulgated the idea of trans-
lating the convenience of DNA microarrays to tissues. 
This new methodology allowed simultaneous screening 
of dozens of tumor specimens at once, being popularly 
called as tissue microarray (TMA) (6).
TMA technology has the potential to significantly ac-
celerate in situ studies of tissue specimens, to explore 
associations between molecular changes and clinic-
pathological informations and to ensure preservation 
of unique and precious research materials. Briefly, tiny 
tissue cylinders are acquired from hundreds of diffe-
rent primary tumor blocks and arranged in a matrix 
configuration within a recipient paraffin block. Sections 
from such TMA blocks can then be used for simulta-
neous in situ analyses of up to 1000 tissue specimens 
either at the DNA, RNA or protein levels; providing 
maximal use of limited tissue resources (3,6-8). 
The use of this high-throughput technique significantly 
facilitates the identification of new molecular mark-
ers that could predict the clinical behavior of tumors, 
helping to better understand their pathogenesis and 
biological characteristics. However, very few studies 
have applied this technology in the evaluation of SGTs, 
and their known morphological heterogeneity could 
theoretically affect the validity of the results obtained. 
Therefore, the objective of this article is to present and 
discuss the design and building of TMA blocks of 238 
SGTs, considering its relevant technical points.  
Material and Methods
From January 2001 to December 2011, 493 cases of SGTs 
were retrieved from the archives of the Oral Pathology 
Department of the Piracicaba Dental School (161 cases) 
and from a Surgical Pathology laboratory of the Brazi-
lian Southern state of Paraná (332 cases). Histological 
preparations stained with H&E were reviewed by three 
oral pathologists and, when necessary, new cuts were 
performed and stained with periodic acid-Schiff and 
mucicarmine. All cases were classified according to the 
2005 World Health Organization’s Histological Typing 
of Salivary Gland Tumors. Those primary SGTs that 
affected major or minor salivary glands were included 
in the study. Cases without enough tissue available for 
TMA construction, or those whose definitive salivary 
gland origin could not be confirmed, were excluded 
from the study. After this selection, 238 formalin-fixed, 
paraffin-embedded primary SGTs remained available 
for being arrayed.
Representative tumor areas were selected and marked 
on H&E-stained sections using an objective marker (1.8 
mm; Nikon Corporation, Tokyo, Japan). The slide was 
then overlaid on the original paraﬃn block to deter-
mine the corresponding area to be used. TMA were 
constructed using a manual tissue arrayer (Sakura Co.; 
Japan). Three representative cylindrical cores of 1.0, 2.0 
or 3.0 mm diameter were taken from each original tis-
sue block and then arrayed sequentially into a recipient 
ready-to-use paraffin block (Sakura Co.; Japan). Two 
cores of normal parotid gland tissue and one of oral sq-
uamous cell carcinoma were inserted into the left up-
per corner of each recipient block as controls for future 
immunohistochemical reactions and for orientation 
when examining the slides. A map specifying the exact 
position of each case was made, to facilitate the inter-
pretation of the histological and immunohistochemical 
results.
The current study has been approved by the Ethical 
Committee of the Piracicaba Dental School – State Uni-
versity of Campinas (Protocol 141/2011).
Results
Among the 238 SGTs used in the construction of the 
TMA blocks, there were 200 benign and 38 malignant 
tumors (Table 1). 72.7% of the cases involved major 
salivary glands (173 cases), whereas 27.3% affected 
intra-oral minor glands (65 cases). It was built 12 TMA 
blocks; from these, it was created 8 blocks of pleomor-
phic adenoma (6 of 2.0mm cores, 1 of 1.0mm cores and 
1 of 3.0mm cores), 1 block of Warthin tumor (2.0mm 
cores) and 1 block containing pleomorphic adenoma, 
Warthin tumor and canalicular adenoma (2.0mm cores). 
The last 2 blocks were composed by 2.0mm cores of 
malignant tumors that included mucoepidermoid carci-
noma, adenoid cystic carcinoma, acinic cell carcinoma, 
polymorphous low-grade adenocarcinoma, epithelial-
myoepithelial carcinoma, myoepithelial carcinoma, car-
cinoma ex-pleomorphic adenoma and adenocarcinoma 
not otherwise specified (Fig. 1). 
Tumors N % 
Benign
  Pleomorphic adenoma 173 72.7 
  Warthin Tumor 24 10.0 
  Canalicular adenoma 3 1.3 
Malignant
  Adenoid cystic carcnoma 10 4.2 
  Mucoepidermoid Carcinoma 10 4.2 
  Adenocarcinoma, Not Otherwise Specified 4 1.� 
  Carcinoma Ex-Pleomorphic Adenoma 4 1.� 
  Polimorphous Low-grade Adenocarcinoma 4 1.7 
  Acinic Cell Carcinoma 3 1.3 
  Epithelial-Myoepithelial Carcinoma 2 0.8 
  Myoepithelial Carcinoma 1 0.4 
Total 238 100.0 
Table 1. Histopathological distribution of the 238 salivary gland 
tumors used for construction of 12 TMA blocks.
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Most of the time and efforts to construct the blocks were 
actually spent in the search, organization and pathologi-
cal review of the tissue specimens to be included in the 
arrays, whereas the TMA building itself usually took 
from 1 to 2 hours for each block depending on the dia-
meter of the cylinders used.  
As expected, the use of larger needles caused more 
damage to the original tissue blocks. Hence, while those 
blocks that provided 1.0mm cores could be used in other 
projects, most of those specimens that provided 3.0mm 
cores could not be used again. In addition, larger nee-
dles substantially reduced the number of specimens that 
could be arrayed. TMA blocks composed by 2.0mm cy-
linders allowed as many as 60 specimens to be arrayed into 
a ready-to-use recipient block of approximately 45x20mm, 
what corresponded to 19 different cases plus controls. 
Those composed by 1.0mm cylinders allowed 120 speci-
mens, representing 39 cases; whereas those TMAs com-
posed by 3.0mm cylinders allowed only 30 specimens or 9 
different cases, always using triplicate arrangement. 
In approximately 5% of the cases there was a slight dif-
ference between the area selected in the H&E-stained 
slide to be inserted in the TMA block and the one that 
in fact was inserted. It was considered that the rate of 
tissue loss attributable to tissue damage during TMA 
construction was about 3.7%.
Most of the tumors were PA, and using three cores, 
highly representative areas of the tumor were obtained 
using either 1.0, 2.0 or 3.0 mm punches (Fig. 2). In tu-
mors with a more homogenous morphological pattern, as 
canalicular adenoma and myoepithelial carcinoma, the 
representativity of the TMA was even higher. However, 
tumors rich in cystic spaces as low-grade mucoepider-
moid carcinoma and Warthin tumor the tissue samples 
were not considered adequate, since only few neoplastic 
tissue was available in the TMA blocks (Fig. 3). 
Fig. 1. Example of full tissue sections previously and after the ac-
quisition of TMA cores of A) 1.0, B) 2.0 and C) 3.0 mm. It can be 
seen that sections that provided larger cylinders became significantly 
more damaged than those that provided smaller cylinders. Micro-
scopic images acquired using the Aperio ScanScope CS scanner.
Fig. 2. Highly representative areas of pleomorphic adeno-
ma in tissue cores of 1.0, 2.0 and 3.0mm. 
Discussion
Tissue microarrays (TMAs) were developed by Konon-
en et al. (5) and are now widely accepted as a fast and 
cost-effective tool that facilitates the analysis of mo-
lecular alterations in thousands of tissue specimens by 
acquiring cylindrical cores of formalin-fixed, paraffin-
embedded tissue specimens and arraying them into a 
recipient block. These TMA blocks can be used for any 
Fig. 3. In cases rich in cystic spaces as low-grade mucoepidermoid 
carcinoma and Warthin tumor, only few neoplastic tissue are found 
on the TMA cores.
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in situ tissue analysis, including IHC, in situ hybridiza-
tion, DNA ploidy, nuclear morphometry, and FISH (9). 
During the last decade, numerous studies have valida-
ted this method in the investigative surgical pathology. 
TMA cores as small as 0.6mm have been confirmed 
to be adequate for analyzing breast cancer specimens 
by IHC for the expression of estrogen and progester-
one receptors and the tyrosine kinase receptor HER-2 
(10,11). Similarly, TMA immunohistochemical staining 
for p53, cyclin D1, bcl-2, bax, Cox-2, β-catenin, c-myc, 
PTEN and p-Akt1enabled high-throughput analysis of 
genetic alterations that might contribute to human colon 
cancer development and progression (12). TMA valida-
tion has also been conducted in endometrial cancer (13), 
esophageal squamous cell carcinoma (14), lung cancer 
(15), cervical adenocarcinoma (16), ovarian carcinoma 
(17) and in many other human neoplasias. 
The use of TMA for molecular studies of SGTs is scarce 
(Table 2) (1, 18-25). Iwafuchi et al. (18) first used TMA 
for analyzing molecular features of these tumors. By 
evaluating the expression of a large panel of proteins 
in different salivary gland neoplasias, these authors 
concluded that SGTs may be well characterized us-
ing markers only toward myoepithelial, luminal and 
basal cells. Also by IHC and TMA, Mcm-2 has been 
proved to be a proliferative sensitive marker for SGTs 
and PLUNC proteins have been suggested to be use-
ful diagnostic tools for mucoepidermoid carcinoma, 
whereas geminin has been strongly associated with re-
duced overall and relapse-free survival rates in patients 
affected by salivary gland carcinomas (1,19,20). Freier 
et al. (21) evaluated KIT expression in a large sample of 
histologically defined subgroups of adenoid cystic car-
cinoma, observing a stronger expression in cribriform 
and tubular subtypes when compared to the solid vari-
ant. Similarly, Freier et al. (22) analyzed the prevalence 
of chromosome 22q13 copy number gains in 70 ACC 
and found that it represents a decisive molecular event 
Authors Country Sample Molecular markers TMA Cores Methods Results Number Size 
Heiduschka et al, 
2011(24) Austria 108 Mcl-1 NS NS IHC 
Parotid gland malignancies produce 
high levels of Mcl-1 protein. 
Clauditz et al, 
2011(23) Germany 1109 HER-2 NS NS FISH, IHC 
HER-2 overexpression was observed in 
about 20% of patients with salivary 
duct cancers. 
Williams et al, 
2010(25) USA 66 HER-2, EGFR, Chromosomes 7 and 17 NS 1.0mm FISH, IHC 
HER-2 gene amplification and protein 
high expression, may be selected for 
targeted therapy. 
Yamazaki et al, 
2010(1) Japan 170 Geminin and Ki-67 02 2.0mm IHC 
Geminin expression is a useful marker 
for predicting salivary gland carcinoma 
aggressiveness. 
Vargas et al, 
2008(20) UK 64 SPLUNC1, SPLUNC2 and LPLUNC1 03 1.0mm IHC 
Presence of an intense expression of 
two PLUNC proteins in mucous cells 
and mucin plugs of mucoepidermoid 
carcinoma and papillary 
cystadenocarcinoma. 
Vargas et al, 
2008(19) UK 62 Mcm-2, Ki-67 and Geminin 03 1.0mm IHC 
Mcm-2 may be a sensitive proliferation 
marker in SGTs and may be useful for 
differential diagnosis. 
Freier et al, 
2005(21) Germany 70 Chromosome 22q13 02 0.6mm FISH 
Copy number gain of 22q13 as a 
frequent nding in ACC irrespective of 
histological variant. 
Freier et al, 
2005(22) Germany 
55 for IHC 
49 for FISH KIT NS 0.6mm FISH, IHC 
Stronger expression in cribriform and 
tubular subtypes if compared to solid 
variant. 
Iwafuchi et al, 
2004(19) Japan 88 
Caldesmon, ?SMA, CD10, calponin, 
CD44v6, Ck7, Ck19, Ck8, p63, Ck14, 
14-3-3? and Maspin 
04 0.6mm IHC 
Salivary gland tumors may be well 
characterized by using makers toward 
only three components, myoepithelial, 
luminal and basal cells. 
Table 2. Studies previously published in the English literature using tissue microarray for molecular analysis of salivary gland tumors.
NS: Not specified; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization; UK: United Kingdom; USA: United States of 
America.
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in early stages of ACC, irrespective of histologic dif-
ferentiation. However, despite these interesting results 
previously described, there are no reports describing 
and evaluating the most important technical points to 
the construction of TMA blocks for studying SGTs.   
TMAs present various relevant advantages for mole-
cular studies of paraffin embedded tissues. It permits 
the concomitant use of a large number of cases and 
significantly reduces the experimental handling time 
(3). Moreover, as the reactions are done in one single 
slide, the reagent concentrations, incubation times, tem-
perature, wash conditions, and antigen retrieval are the 
same for all specimens. The necessary reagent volume 
is significantly reduced, making it a very cost-effective 
method (6,26). In our study, using ready-to-use recipient 
TMA blocks, it was possible to resume our whole 238 
neoplastic samples to only 12 blocks, facilitating the 
evaluation of molecular markers in this large number of 
cases. In addition, the use of TMAs preserves precious 
and finite tissue resources and maximizes the number 
of experiments that can be performed with the material 
present in one paraffin block (6).
Whereas large tissue sections are used for histological 
diagnosis, TMA has been reserved for research pur-
poses. However, tumor heterogeneity has traditionally 
been recognized as a potential problem for those using 
TMAs, and the most used 0.6mm cores have been per-
ceived as too small and potentially not representative of 
the entire specimen. Taking multiple samples of each 
tumor seems to be the most direct way of combating 
the potential lack of representativeness in a certain tis-
sue (7). Recent reports achieved 95% accuracy with 
only two cores, whereas most studies indicate that trip-
licate TMA cores have up to 98% concordance when 
compared with the results of full sections (3,16). Other 
alternative would be the use of larger punch needles; 
however, the increase in the number of cores and their 
diameters leads to a considerable damaged donor block 
and fewer samples arrayed (�). Evaluating the histologi-
cal features present in the cores obtained in the present 
study, it could be noted that triplicate cores of 1.0, 2.0 
and 3.0mm were all well representative of the original 
tissue, although 3.0mm cores evidently offered more 
neoplastic cells and structures to be evaluated than 1.0 
and 2.0mm cores. However, only 9 cases could be in-
serted in a TMA recipient block when 3mm cylinders 
were used, whereas up to 39 could be arrayed when 
1mm were taken; moreover, smaller diameters better 
preserved the donor blocks for future studies.
Improper selection of representative tumor areas on 
the H&E original slide by the pathologist, or incorrect 
punching of these representative areas can cause tissue 
cores that contain inadequate areas to be studied (6). In 
the current study, it was noted that in a small percent-
age of cases, the neoplastic area inserted in the recipient 
block was not the exact area selected in the H&E slide, 
what may also be attributable to differences in the tissue 
contraction in the original paraffin donor block.
Finally, due to the small size of the cylinders and the 
high number of samples, TMA cores are much more 
prone to be lost during sectioning than full sections. 
The total number of lost cores due to technical reasons 
has been estimated to vary from 4 to 23% (14,16,27). In 
the building process of the TMA blocks in the present 
study, 3.7% of the cores were lost; however, this rate 
would probably increase if the samples were submitted 
to IHC procedures. 
In conclusion, tissue microarray is a high-throughput, 
cost-effective and tissue-saving technique in molecular 
analysis of formalin-fixed, paraffin-embedded neopla-
sias, helping to overcome the ordinary time-consuming 
work. The present study showed the usefulness of this 
technique in the construction of SGTs TMA blocks, re-
vealing that solid tumors are more indicated to be mi-
cro-arrayed than their cystic counterparts. These TMA 
blocks will now be used for immunohistochemical stud-
ies to better evaluate SGT’s molecular features.
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